hers glp 1 oral introduces GLP-1 weight loss membership starting at $39 Novo Nordisk Drops Hims &

Each one contributes to a safer, more comfortable injection

If it is a class effect, switching medications within the same class would not help

A permanent microdose strategy with promises of same results, less drug is not backed by randomized trials

Human trials are ongoing, but even modest effects in opioid use disorder could be clinically meaningful given the favorable safety profile of GLP-1 drugs compared with existing treatments

16.0 kPa) compared to PBO (n=7) (Table 1)

Real needle-free GLP-1 exists: the Wegovy oral tablet (oral semaglutide 25 mg, FDA-approved December 2025, 13.6% weight loss in the OASIS 4 trial) and experimental microneedle patches from Daewoong Therapeutics (80% bioavailability in a 70-person Phase 1 study, 2028-2030 market estimate)